Altavant has an active preclinical research program to discover and develop 3rd generation TPH1 inhibitors that have different product profiles or that feature different routes of administration. Potential improvements to the 3rd generation compounds include increasing potency against TPH1 and modification of the molecules’ physiochemical properties to increase bioavailability of the drug. With this program, we believe Altavant can harness the full potential of TPH1 inhibitors in treating human disease.

For references related to experimental approaches to treat PAH and clinical articles specifically related to rodatristat, please visit our Publications page. *For ease of reading, this website sometimes uses the name “rodatristat” to refer to the prodrug rodatristat ethyl in addition to the active moiety.